Program Overview
University of Melbourne spinout Fluent has secured A$2 million in seed funding to accelerate development of its minimally invasive brain-computer interface designed to restore communication for individuals with neurological disorders that impair speech.
The company emerged from the University of Melbourne’s innovation ecosystem, progressing through Proof of Concept funding, the Melbourne Entrepreneurial Centre accelerator, and the University’s Genesis Pre-Seed Fund before attracting investment from Pacific Channel, Galileo Ventures, Multiple Sclerosis WA, Professor David Graydon, Jumpspace Ventures, and Founders Factory.
According to Professor Mark Cassidy, Deputy Vice-Chancellor at the University of Melbourne:
“Fluent was born out of the University’s innovation ecosystem with its researchers securing Proof of Concept funding, nurtured by the Melbourne Entrepreneurial Centre’s accelerator program and now securing investment to develop human clinical trials.”
Strategic Relevance for GAP Leaders
Fluent illustrates an effective university commercialization pathway that begins with academic research, progresses through proof-of-concept funding and accelerator support, attracts institutional pre-seed and venture investment, and ultimately advances toward clinical validation.
For GAP leaders, the company demonstrates how layered commercialization support can substantially reduce technical and investment risk for complex medical devices while preparing technologies for first-in-human studies. It also highlights the growing opportunity in neurotechnology, where AI, biomedical engineering, and translational research are converging to create entirely new therapeutic markets.
Innovation & Technology
Founded by Dr. Tim Mahoney, Fluent has developed a minimally invasive brain-computer interface that enables people with conditions such as motor neurone disease and multiple sclerosis to communicate by translating intended speech into text or audio.
Unlike traditional brain-computer interfaces that require electrodes to be implanted inside the skull, Fluent’s device is positioned beneath the scalp but outside the skull, significantly reducing surgical complexity while maintaining comparable signal quality.
The platform combines implantable neural sensing, machine learning, speech decoding, and real-time signal processing to interpret activity in the motor cortex during attempted speech. Preliminary studies demonstrated 96% phrase identification accuracy across a library of 128 phrases using one of the largest English-language speech intention datasets developed to date. Human clinical studies are scheduled to begin later this year.
Potential Market Applications
Fluent – Minimally Invasive Brain-Computer Interface
Founder & CEO: Dr. Tim Mahoney
University Origin: University of Melbourne
Market Applications
• Assistive communication technologies: Restoring communication for patients with motor neurone disease, multiple sclerosis, stroke, and other neurological disorders causing speech loss.
• AI-powered neurotechnology platforms: Machine learning systems translating neural activity into real-time speech, text, or digital communication.
• Next-generation implantable medical devices: Lower-risk brain-computer interfaces designed to expand patient access through less invasive implantation procedures.
Read the Full Story
Related Topics
brain-computer interfaces, neurotechnology commercialization, university spinouts, medical device innovation, assistive technologies, AI healthcare, proof-of-concept funding
